Profound Medical (PROF) Q4 2025 earnings review
Record Revenue Masking a Startling Decline in Recurring Sales
Profound Medical delivered record Q4 revenue of $6.0M, growing 43% YoY and 13% sequentially. However, examining the mix reveals a concerning divergence: the beat was entirely driven by a 145% surge in one-time capital equipment sales, while high-margin recurring revenue actually declined 14% YoY. This is a red flag for a 'razor/razorblade' model, especially as the installed base grew to 78 systems. Despite these mix issues and a compressed gross margin of 67%, the balance sheet was fortified with a ~$42M equity raise in December, providing a $59.7M cash runway to execute on a guided ~54% expansion of the installed base in 2026.
🐂 Bull Case
The transition to a capital sales model is finally yielding results. Capital revenue hit $3.68M in Q4 (up from $1.5M YoY). A qualified pipeline of 110 systems gives management confidence to project reaching 120 active installs by year-end 2026.
Level 1 data from the CAPTAIN randomized trial is scheduled for a late-breaking presentation at the EAU Congress in March 2026. Positive superiority data over robotic surgery could dramatically accelerate commercial payer coverage and guideline inclusion.
🐻 Bear Case
Recurring revenue (consumables, service) fell 14% YoY in Q4 to $2.3M, despite the installed base growing. If per-system utilization is falling, the long-term high-margin profitability model is at risk.
Gross margins dropped to 67% from 71% a year ago, dragged down by product mix and international introductory pricing. Full-year operating cash burn expanded to $38.2M, requiring persistent top-line acceleration to reach breakeven.
⚖️ Verdict: ⚪
Neutral. The capital sales pipeline and balance sheet fortification are clear positives, and upcoming clinical readouts offer massive upside. However, the unexplained drop in recurring revenue completely contradicts the narrative of increasing system utilization and must be clarified before adopting a heavily bullish stance.
Key Themes
Reversing Trend in Recurring Revenue
The most glaring anomaly in the Q4 print is the performance of the recurring revenue segment. It dropped to $2.30M in 25Q4, down from $2.68M in 24Q4 and $4.07M in 25Q3. Given management previously touted growing same-store utilization and a growing installed base (now at 78), a decline in consumable sales requires intense scrutiny. It could point to temporary inventory destocking at hospitals, seasonality, or a more systemic issue with procedure adoption post-installation.
TULSA-AI for BPH Triples Addressable Market
The full launch of the TULSA-AI Volume Reduction module at the RSNA meeting in Q4 is a major structural driver. By reducing procedure times to 60-90 minutes, TULSA becomes economically competitive with mainstream BPH treatments (Rezum, Aquablation). Management estimates this expands their Total Addressable Market (TAM) from ~200,000 prostate cancer patients to roughly 600,000 total prostate disease patients annually.
Global Distribution Footprint Expanding
Profound is actively shifting away from a purely direct U.S. model to a hybrid global approach. In Q4, they signed exclusive distribution and supply agreements in Saudi Arabia (with Al Faisaliah Group) and Australia/New Zealand (with Getz Healthcare), while regaining direct rights in Canada. This geographic expansion diversifies revenue, though it temporarily weighed on Q4 gross margins due to introductory pricing.
Gross Margin Decelerating Due to Mix
Gross margin dropped to 67% in Q4 from 74% in Q3 and 71% in the prior year. Management explicitly cited 'product mix' (higher weighting of capital sales vs. consumables) and new market introductory prices. If capital sales continue to dominate the growth mix to hit the 120-install target, investors should expect blended gross margins to remain suppressed compared to the historical >70% targets.
CAPTAIN Trial Setup for Major Readout
The company announced that Level 1 post-market CAPTAIN trial data (comparing TULSA to robotic radical prostatectomy) will be presented at the EAU Congress in March 2026. Previous perioperative glimpses showed TULSA eliminated blood loss and overnight hospital stays. Formal publication of these outcomes is the linchpin strategy for securing broad private payer coverage.
Other KPIs
Accelerating significantly from $40.1M in FY24. This 31% YoY increase outpaced the gross profit growth, leading to a wider operating loss. The bloat was driven by increased headcount, commercial sales force expansion, commissions, and heavy R&D/travel costs associated with the CAPTAIN trial.
Widened from $27.8M in FY24. While top-line revenue grew 51%, the aggressive commercial infrastructure build and transition to a capital sales model required heavy upfront investment. Q4 net loss specifically was $8.2M, up from $4.9M YoY.
Strengthened via a $36.0M registered direct offering in the U.S. and a $6.45M private placement in Canada in December. Despite burning $38.2M in operating cash flow during FY25, this injection secures the balance sheet to fund the commercial launch of the BPH module and support the capital sales cycle into 2026.
Guidance
Accelerating. Following FY25's 51% revenue growth, management's commentary implies a target of 70% to 100%+ growth for FY26. This relies heavily on closing the 110-system qualified pipeline and driving consumable utilization via the newly launched BPH software.
Accelerating. Growing from 78 systems at the end of 2025 implies adding roughly 42 net new systems in 2026. This is a significant step-up in commercial execution, representing ~54% base growth.
Key Questions
Recurring Revenue Disconnect
Total revenue hit a record, but recurring revenue dropped 14% YoY in Q4 despite an 11-system sequential jump in the installed base. Was this driven by inventory management, a drop in per-site utilization, or pricing changes on consumables?
Margin Impact of Global Expansion
You noted introductory pricing in Saudi Arabia and Australia pressured Q4 gross margins. How long are these introductory pricing periods expected to last, and what is the normalized margin expectation for international distribution deals versus direct U.S. sales?
Cash Runway to Profitability
With the $42 million raised in December, the cash balance is roughly $60 million. Given the $38 million operating burn in 2025, does this current capitalization bridge the company entirely to cash flow breakeven, or should investors expect another raise in 2026?